LYKA LABS LTD.

Kunal Gandhi, along with Persons Acting in Concert (PACs), has acquired an additional 14,176 shares, representing 0.04% of the total share capital, in Lyka Labs Limited through open market transactions. This acquisition increases the total holding of Kunal Gandhi and PACs to 57,91,851 shares, or 16.23% of the company's total equity. The acquisition was completed on June 29, 2026. The total equity share capital of Lyka Labs remains unchanged at 3,56,90,000 equity shares.

Lyka Labs Ltd has announced that Mr. Kunal N. Gandhi, a Promoter, has acquired 14,176 equity shares of the company through open market purchases on June 29, 2026. This disclosure has been made in compliance with Regulation 7(2)(a) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The company has enclosed the necessary disclosures and requested that they be taken on record and forwarded to both the BSE and NSE.

Kunal Gandhi and associated entities have disclosed an acquisition of 55,967 shares, representing 0.15% of the total share capital in Lyka Labs Limited. This transaction, executed via the open market, increases the collective holding of the acquirer and Persons Acting in Concert (PACs) from 16.03% to 16.19%. The acquisition involved equity shares carrying voting rights. The total share capital of Lyka Labs remains unchanged at 3,56,90,000 equity shares.

Lyka Labs Ltd has received disclosures from its promoters, including Mr. Kunal N. Gandhi, Mrs. Nehal N Gandhi, Mrs. Alisha K. Gandhi, and Enai Trading and Investment Private Limited, regarding their acquisition of equity shares. Mr. Kunal Gandhi acquired 6,533 shares on June 25, 2026, and Mrs. Alisha Gandhi acquired 5,000 shares on June 24, 2026, both through open market purchases. These disclosures are made in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, specifically Regulation 7(2)(a) read with Regulation 6(2). The company is forwarding these disclosures to the BSE and NSE.

Lyka Labs Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from Wednesday, July 1, 2026, and will remain in effect until 48 hours after the announcement of the Unaudited Financial Results for the first quarter ending June 30, 2026. The restriction applies to all 'Designated Persons' and their immediate relatives, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Lyka Labs Ltd has received a Show Cause-cum-Demand Notice from the CGST & Central Excise office, Mumbai East, for ₹73,22,077. The demand arises from an alleged erroneous refund claim of Integrated Goods and Services Tax (IGST) on exports made under Advance Authorizations, which the notice claims contravened Rule 96(10) of CGST Rules, 2017, resulting in a double benefit. The company disputes the demand, citing the omission of Rule 96(10) from October 2024, and states there is no material impact on its financials or operations as it defends the allegations.

Lyka Labs Ltd has approved the allotment of 4,62,711 equity shares of face value Rs. 10 each to the shareholders of Lyka Exports Limited, as per the approved scheme of amalgamation. This allotment is in the ratio of 23 shares of Lyka Labs for every 100 shares held in Lyka Exports. The company's paid-up equity share capital has increased to Rs. 36.15 crore. These new shares will rank pari-passu with existing shares and are proposed for listing on BSE and NSE.

Lyka Labs Ltd has responded to an exchange query regarding recent significant price movement in its securities. The company stated that there are no material information or events requiring disclosure under SEBI regulations that would explain the price fluctuation. Lyka Labs confirmed its regular compliance with SEBI disclosure requirements and its practice of disseminating relevant information when necessary.

Lyka Labs Limited has received a favorable order from the National Company Law Appellate Tribunal (NCLAT), New Delhi. The order mandates Modi Life Care Industries Limited to pay Lyka Labs a claim amount of ₹63,00,000/- within 30 days. This legal victory pertains to Company Appeal (AT) INS.NO. 726 of 2024 filed under the Insolvency and Bankruptcy Code, 2016. The company stated that this receipt is the primary impact on its financials, with no other material effect on its operations or activities.

Lyka Labs Ltd's board approved recognizing an impairment loss of ₹2301.44 Lakhs on its investment and loans to subsidiary Lyka BDR International Limited due to continuous operational losses and eroding net worth. The company's financial exposure in Lyka BDR stands at ₹2301.44 Lakhs, including equity investment of ₹1469.05 Lakhs and unsecured loan of ₹832.39 Lakhs. The board also approved audited financial results for the quarter and year ended March 31, 2026, and fixed June 04, 2026, as the record date for equity share allocation pursuant to the scheme.